- Home
- BVS vs CRVS Comparison
BVS vs CRVS Comparison
Compare BVS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVS
- CRVS
- Stock Information
- Founded
- BVS 2011
- CRVS 2014
- Country
- BVS United States
- CRVS United States
- Employees
- BVS N/A
- CRVS N/A
- Industry
- BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BVS Health Care
- CRVS Health Care
- Exchange
- BVS Nasdaq
- CRVS Nasdaq
- Market Cap
- BVS 432.7M
- CRVS 459.0M
- IPO Year
- BVS 2021
- CRVS 2016
- Fundamental
- Price
- BVS $7.23
- CRVS $5.83
- Analyst Decision
- BVS Strong Buy
- CRVS Strong Buy
- Analyst Count
- BVS 5
- CRVS 4
- Target Price
- BVS $14.40
- CRVS $15.00
- AVG Volume (30 Days)
- BVS 388.8K
- CRVS 596.5K
- Earning Date
- BVS 11-04-2025
- CRVS 11-11-2025
- Dividend Yield
- BVS N/A
- CRVS N/A
- EPS Growth
- BVS N/A
- CRVS N/A
- EPS
- BVS 0.03
- CRVS N/A
- Revenue
- BVS $564,142,000.00
- CRVS N/A
- Revenue This Year
- BVS N/A
- CRVS N/A
- Revenue Next Year
- BVS $6.84
- CRVS N/A
- P/E Ratio
- BVS $261.09
- CRVS N/A
- Revenue Growth
- BVS 5.08
- CRVS N/A
- 52 Week Low
- BVS $5.81
- CRVS $2.54
- 52 Week High
- BVS $14.38
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- BVS 52.04
- CRVS 58.56
- Support Level
- BVS $6.98
- CRVS $5.90
- Resistance Level
- BVS $7.33
- CRVS $6.30
- Average True Range (ATR)
- BVS 0.27
- CRVS 0.32
- MACD
- BVS -0.03
- CRVS -0.00
- Stochastic Oscillator
- BVS 32.89
- CRVS 53.92
About BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).